• Oxaliplatin: Platinum-Based Chemotherapeutic Agent Profile

  2026-08-06

  Oxaliplatin is a platinum-based chemotherapeutic agent with proven efficacy in metastatic colorectal cancer therapy. It induces apoptosis via DNA adduct formation and is widely used in both preclinical and clinical oncology research. Its unique mechanism differentiates it from other platinum compounds, notably with distinct resistance patterns.

• Liproxstatin-1: Precision Ferroptosis Inhibitor in Research

  2026-08-05

  Liproxstatin-1 empowers researchers to dissect ferroptosis with nanomolar precision and robust protection in GPX4-deficient and oxidative stress models. Discover protocol-driven insights and troubleshooting strategies for maximizing its impact in organ injury, neurodegeneration, and beyond.

• Non-Invasive Cephalopod Sex Genotyping via qPCR: A New Stand

  2026-08-05

  Rubino et al. present a robust, non-invasive quantitative PCR method for sex genotyping in diverse cephalopod species, relying on skin swabs and dosage analysis of Z-chromosome content. This approach enables accurate, early-life sex determination, supporting sustainable research and aquaculture management.

• Epoxomicin in PQC: Precision Tools for ER Stress and Transla

  2026-08-04

  This article explores the mechanistic underpinnings and translational potential of Epoxomicin as a selective, irreversible proteasome inhibitor. It connects recent findings on ER stress, protein quality control, and the role of N-recognins UBR1/UBR2, guiding researchers on designing robust ubiquitin-proteasome pathway studies. Strategic protocol advice and industry context elevate this piece beyond standard product overviews.

• BET Inhibition Alters HPV-16+ HNSCC Gene Expression and Cell

  2026-08-04

  This study explores how BET protein inhibition impacts gene expression and cell cycle regulation in HPV-16-associated head and neck squamous cell carcinoma (HNSCC). The findings reveal heterogeneous transcriptional responses to BET inhibition, including downregulation of viral oncogenes and cell cycle arrest, offering insights for targeted epigenetics research in cancer biology.

• Targeted Amikacin Delivery to Granulomas via Dendritic Cells

  2026-08-03

  This study demonstrates that dendritic cells loaded with amikacin can deliver high concentrations of the antibiotic directly into granulomas formed during Mycobacterium avium infection, minimizing systemic exposure. The findings highlight a promising strategy for increasing therapeutic efficacy against non-tuberculous mycobacterial infections while reducing toxicity.

• BMP4-GPX4 Axis Mitigates Ferroptosis in Glaucoma Models

  2026-08-03

  This study identifies the BMP4-GPX4 pathway as a critical regulator of ferroptosis in retinal ganglion cells (RGCs) and demonstrates its capacity to enhance RGC differentiation from transplanted retinal stem cells in high intraocular pressure glaucoma. The findings propose a mechanistic approach for neuroprotection and improved stem cell therapy outcomes in neurodegenerative eye disease models.

• Tiamulin as a Small-Molecule TNF-α Inhibitor in Psoriasis Mo

  2026-08-02

  The referenced study establishes Tiamulin fumarate as a direct small-molecule inhibitor of TNF-α-mediated inflammatory pathways, demonstrating its efficacy in alleviating psoriasis-like dermatitis in vitro and in vivo. This work opens new avenues for repurposing Tiamulin beyond veterinary use, particularly in targeting NF-κB and MAPK signaling in inflammatory skin diseases.

• Estramustine Dose Compliance in Degarelix-Based Neoadjuvant

  2026-08-01

  This prospective clinical study reveals that strict dose compliance with estramustine phosphate, when combined with neoadjuvant degarelix acetate, significantly predicts biochemical recurrence in very high-risk prostate cancer patients undergoing robot-assisted radical prostatectomy. The findings highlight the prognostic importance of chemohormonal regimen adherence and inform risk-adapted approaches for managing advanced prostate cancer.

• (-)-JQ1 in Epigenetics Research: Protocols, Controls & Troub

  2026-07-31

  (-)-JQ1, the inactive JQ1 stereoisomer, is the rigorously validated gold-standard negative control for BET bromodomain inhibition studies. This guide delivers hands-on protocol enhancements, troubleshooting insights, and practical workflow recommendations to ensure experimental specificity and reproducibility in cancer biology and epigenetics research.

• Dual Inhibition of FUBP1–FUSE and Topoisomerase I by SN-38 i

  2026-07-31

  The referenced study reveals that 7-Ethyl-10-hydroxycamptothecin (SN-38) and camptothecin not only act as DNA topoisomerase I inhibitors but also directly disrupt the binding of the oncoprotein FUBP1 to its DNA target FUSE. This dual mechanism offers new insights into apoptosis induction and broadens the molecular basis for advanced colon and hepatocellular cancer research.

• SIS3 (Smad3 Inhibitor): Precision Dissection of TGF-β Pathwa

  2026-07-30

  Discover how SIS3, a selective Smad3 inhibitor, empowers fibrosis and osteoarthritis research by enabling precise interrogation of TGF-β signaling. This article uniquely analyzes SIS3’s protocol considerations and translational impact beyond current reviews.

• Dorsomorphin 2HCl: Applied AMPK Inhibition in Metabolic Work

  2026-07-30

  Dorsomorphin 2HCl empowers researchers to dissect complex metabolic and bone signaling networks through precise AMPK and BMP pathway inhibition. This article delivers practical protocols, troubleshooting strategies, and data-driven insights to optimize preclinical workflows in lipid metabolism, osteogenesis, and iron homeostasis research.

• Nintedanib (BIBF 1120): Optimizing Antiangiogenic Workflows

  2026-07-29

  Nintedanib (BIBF 1120) enables precise, reproducible inhibition of VEGFR, PDGFR, and FGFR signaling, directly supporting advanced cancer and fibrosis models. This guide distills evidence-backed protocols, troubleshooting insights, and practical assay tips—especially for ATRX-deficient tumor research.

• Shufeng Xingbi Therapy Restores Immunity and Microbiota in A

  2026-07-29

  This study investigates the ability of Shufeng Xingbi Therapy (SFXBT) to rebalance Th1/Th2 immune responses and modulate intestinal flora in a rat model of allergic rhinitis. The findings reveal mechanistic links between immune modulation, microbial composition, and the mitigation of allergic symptoms, providing a basis for future translational research.

551 records 9/37 page Previous Next First page 上5页 678910 下5页 Last page